Basic Information
PARNIDO PROLONGED-RELEASE TABLETS 6MG
TABLET, MULTILAYER, EXTENDED RELEASE
Regulatory Information
SIN16782P
May 15, 2023
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XN05AX13
Company Information
SINGAPORE PHARMACEUTICAL PRIVATE LIMITED
SINGAPORE PHARMACEUTICAL PRIVATE LIMITED
Active Ingredients
Paliperidone
Strength: 6.00mg
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance, risperidone, or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** Parnido is indicated for the treatment of schizophrenia. Parnido is indicated for the acute treatment of schizoaffective disorder as monotherapy and as an adjunct to antidepressants and/or mood stabilizers.